Patent number: 6639074
Abstract: The present invention relates to new, efficient processes for the preparation of 5-(2-oxazolylalkylthio)-2-azacycloalkanoylaminothiazole compounds of formula I
or a pharmaceutically acceptable salt thereof, wherein:
R is alkyl, aryl or heteroaryl;
R1, R2, R3, R4 and R5 are each independently hydrogen, alkyl, aryl or heteroaryl;
R6 and R7 are each independently hydrogen, alkyl, aryl, heteroaryl, halogen, hydroxy or alkoxy;
R8 is hydrogen, alkyl, aryl, heteroaryl, CONR9R10, COR11 or COOR12;
R9, R10, R11 and R12 are each independently hydrogen, alkyl or aryl;
m equals 0 to 5; and
n equals 0 to 5,
which are novel, potent inhibitors of cyclin dependent kinases (cdks). The present invention further concerns new key intermediate compounds, a quaternary ammonium salt of formula III′ and a 2-oxazolylalkyl derivative of formula IX.
Type:
Grant
Filed:
March 18, 2002
Date of Patent:
October 28, 2003
Assignee:
Bristol Myers Squibb Company
Inventors:
Bang-Chi Chen, Kyoung S. Kim, S. David Kimball, Raj N. Misra, Mark E. Salvati, Joseph E. Sundeen, Hai-Yun Xiao, Rulin Zhao